Press Release Archives
ASEAN News: Epeius Biotechnologies Gains Commercial Approval For Rexin-G®, A Tumor-Targeted Gene-Based Medicine For Metastatic Cancer
December 18, 2007 PDF Version
FDA Approves The Opening Of A Phase II Registration Protocol Using Rexin-G® For Osteosarcoma In California U.S.A.
November 5, 2007 PDF Version
California Biotechnology Company Takes Aim At Pancreatic Cancer With An Advanced Phase I/Ii Clinical Trial Using Rexin-G™, A Targeted Injectable Gene Delivery System
July 10, 2007 PDF Version
Epeius Biotechnologies Reaches Out To American Cancer Patients, Gains FDA Approval For Two New Clinical Trials Using Rexin-G (Tm) For Breast Cancer And Sarcoma
June 4, 2007 PDF Version
News From The Battlefield Of Metastatic Cancer: Epeius Biotechnologies Draws The Sword Of Targeted Gene Delivery (Rexin-G) From The Stone Of Chemistry And Physics
June 4, 2007 PDF Version
Epeius Biotechnologies To Present The Advent Of Tumor Targeting Technology And The Clinical Development Of Its Lead Anti-Cancer Agent, Rexin-G, At Upcoming Bioventure, Nanotechnology & Nanomedicine Conferences .
May 15, 2007 PDF Version
Japanese study confirms safety and efficacy of intravenous Rexin-G as treatment for diverse metastatic cancers.
December 6, 2006 PDF Version (28kb)
Epeius Biotechnologies affirms leadership role in the development of genetic medicine: accepts invitations to speak at two prestigious industry conferences.
October 10, 2006 PDF Version (26kb)
Epeius Biotechnologies gains federal support for landmark clinical trials of tumor-targeted gene therapy using Rexin-G.
October 2, 2006 PDF Version (24.8kb)
Epeius Biotechnologies receives accelerated approval for Rexin-G in the Philippines
August 10, 2006 PDF Version (23.8kb)
Epeius Biotechnologies initiates Tri-Rex vaccination protocols for breast cancer.
July 4, 2006 PDF Version (27.1kb)
Epeius Biotechnologies receives $400,000 grant to support gene therapy trials for pancreatic cancer.
June 19, 2006 PDF Version (24.1kb)
Expanded access program for Rexin-G provides genetic medicine to cancer patients, first revenues for Epeius Biotechnologie
April 7, 2006 PDF Version (15kb)
Epeius Biotechnologies establishes corporate headquarters in San Marino, California - Facilities include a Clinical Research Unit dedicated to evaluating new genetic medicine for cancer.
April 4, 2006 PDF Version (44.6kb)
Clinical Trial for pancreatic cancer opens at Mayo Clinic using tumor-targeted gene therapy vector Rexin-G, the world's first tumor-targeted gene delivery vector.
July 14, 2005 PDF Version (13.9kb)
Phase I Clinical Trial for advanced colon and pancreatic cancer opens in New York using Rexin-G, the world's first tumor-targeted gene delivery vector.
April 4, 2005 PDF Version (6.5kb)
First American Gains Therapeutic Benefit From Rexin-G, the leading tumor-targeted Gene Therapy Vector for Pancreatic Cancer.
May 11, 2004 PDF Version (93.8kb)
Epeius Biotechnologies corporation gains FDA orphan drug approval for Rexin-G, the world's first targeted injectable gene therapy vector, for Pancreatic Cancer.
August 22, 2003 PDF Version (77kb)
Epeius Biotechnologies Corporation today announced that clinical trials have started in Manila, testing the world's first targeted injectable gene delivery system for treating metastatic cancer, using Epeius' TDS technologies.
June 3, 2003 PDF Version (17.8kb)
You must have Adobe Acrobat Reader to view PDF files.
You may download it for free by clicking here.
